Premedication with clarithromycin is effective against secondary bacterial pneumonia during influenza virus infection in a pulmonary emphysema mouse model

Journal of Pharmacology and Experimental Therapeutics

Volumn 358, Issue 3, 2016, Pages 457-463

  Harada, Tatsuhiko ^a,b,d   Ishimatsu, Yuji ^b   Hara, Atsuko ^b,d   Morita, Towako ^b,d   Nakashima, Shota ^b,d   Kakugawa, Tomoyuki ^b,d   Sakamoto, Noriho ^b,c,d   Kosai, Kosuke ^c   Izumikawa, Koichi ^a   Yanagihara, Katsunori ^c   Mukae, Hiroshi ^b,c,d   Kohno, Shigeru ^b,d  

^a Unit of Molecular Microbiology and Immunology   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c Department of Respiratory Medicine ^*  (Japan)

^d NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; GAMMA INTERFERON; CHEMOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM IDENTIFICATION; BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; INFLUENZA; INFLUENZA VIRUS; INOCULATION; LUNG EMPHYSEMA; LUNG HOMOGENATE; LUNG LAVAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; VIRUS IDENTIFICATION; VIRUS STRAIN; VIRUS TITRATION; ANIMAL; BACTERIAL LOAD; CELL COUNT; COINFECTION; COMPLICATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); LUNG; METABOLISM; MICROBIOLOGY; NEUTROPHIL; ORTHOMYXOVIRUS INFECTION; PHYSIOLOGY; PNEUMONIA, BACTERIAL; SURVIVAL ANALYSIS; VIROLOGY; VIRUS LOAD;

ANIMALS; BACTERIAL LOAD; CELL COUNT; CHEMOKINES; CLARITHROMYCIN; COINFECTION; DISEASE MODELS, ANIMAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; LUNG; MICE; NEUTROPHILS; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMONIA, BACTERIAL; PULMONARY EMPHYSEMA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 84983778907     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.233932     Document Type: Article

References (41)

1. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, and Lazarus SC, et al. COPD Clinical Research Network (2011) Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365: 689-698.
2. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, and Kettner JD, et al.; Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza (2010) Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl JMed 362:1708-1719.
3. Brundage JF and Shanks GD (2008) Deaths from bacterial pneumonia during 1918-49 influenza pandemic. Emerg Infect Dis 14:1193-1199.
4. Cilloniz C, Pantin-Jackwood MJ, Ni C, Carter VS, Korth MJ, Swayne DE, Tumpey TM, and Katze MG (2012) Molecular signatures associated with Mx1-mediated resistance to highly pathogenic influenza virus infection: mechanisms of survival. J Virol 86:2437-2446.
5. Dai MY, Qiao JP, Xu YH, and Fei GH (2015) Respiratory infectious phenotypes in acute exacerbation of COPD: An aid to length of stay and COPD Assessment Test. Int J Chron Obstruct Pulmon Dis 10:2257-2263.
6. Donath E, Chaudhry A, Hernandez-Aya LF, and Lit L (2013) A meta- Analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with chronic obstructive pulmonary disease. Respir Med 107:1385-1392.
7. Fukuda Y, Yanagihara K, Higashiyama Y, Miyazaki Y, Hirakata Y, Mukae H, Tomono K, Mizuta Y, Tsukamoto K, and Kohno S (2006) Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur Respir J 27:1020-1025.
8. Galani IE and Andreakos E (2015) Neutrophils in viral infections: current concepts and caveats. J Leukoc Biol 98:557-564.
9. Herold S, Becker C, Ridge KM, and Budinger GR (2015) Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur Respir J 45:1463-1478.
10. Kanoh S and Rubin BK (2010) Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 23:590-615.
11. Kikuchi E, Yamazaki K, Kikuchi J, Hasegawa N, Hashimoto S, Ishizaka A, and Nishimura M (2008) Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid. Respirology 13:221-226.
12. Kurai D, Saraya T, Ishii H, and Takizawa H (2013) Virus-induced exacerbations in asthma and COPD. Front Microbiol 4:293.
13. Lee B, Robinson KM, McHugh KJ, Scheller EV, Mandalapu S, Chen C, Di YP, Clay ME, Enelow RI, and Dubin PJ, et al. (2015) Influenza-induced type I interferon enhances susceptibility to gram-negative and gram-positive bacterial pneumonia in mice. Am J Physiol Lung Cell Mol Physiol 309:L158-L167.
14. LeMessurier KS, Häcker H, Chi L, Tuomanen E, and Redecke V (2013) Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung. PLoS Pathog 9:e1003727.
15. Li W, Moltedo B, and Moran TM (2012) Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gd T cells. J Virol 86:12304-12312.
16. Mathers CD and Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:e442.
17. McCarty JM (2000) Clarithromycin in the management of community- Acquired pneumonia. Clin Ther 22:281-294, discussion 265.
18. Miyamoto D, Hasegawa S, Sriwilaijaroen N, Yingsakmongkon S, Hiramatsu H, Takahashi T, Hidari K, Guo CT, Sakano Y, and Suzuki T, et al. (2008) Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells. Biol Pharm Bull 31:217-222.
19. Morens DM, Taubenberger JK, and Fauci AS (2008) Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 198:962-970.
20. Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, and Aguet M (1994) Functional role of type I and type II interferons in antiviral defense. Science 264:1918-1921.
21. Murata Y, Walsh EE, and Falsey AR (2007) Pulmonary complications of interpandemic influenza A in hospitalized adults. J Infect Dis 195:1029-1037.
22. Nakamura S, Davis KM, and Weiser JN (2011) Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J Clin Invest 121:3657-3665.
23. Ni W, Shao X, Cai X, Wei C, Cui J, Wang R, and Liu Y (2015) Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: A meta- Analysis. PLoS One 10:e0121257.
24. Otsu Y, Yanagihara K, Fukuda Y, Miyazaki Y, Tsukamoto K, Hirakata Y, Tomono K, Kadota J, Tashiro T, and Murata I, et al. (2003) In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. Antimicrob Agents Chemother 47:3699-3703.
25. Partridge J and Kieny MP (2013) Global production capacity of seasonal influenza vaccine in 2011. Vaccine 31:728-731.
26. Reed LJ and Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493-497.
27. Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, Gillissen A, Bufe A, and Schultze-Werninghaus G (2003) Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: A case-control study. Thorax 58:37-42.
28. Sapey E and Stockley RA (2006) COPD exacerbations. 2: Aetiology. Thorax 61: 250-258.
29. Sato K, Suga M, Akaike T, Fujii S, Muranaka H, Doi T, Maeda H, and Ando M (1998) Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. Am J Respir Crit Care Med 157:853-857.
30. Schroder K, Hertzog PJ, Ravasi T, and Hume DA (2004) Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol 75:163-189.
31. Seki M, Kohno S, Newstead MW, Zeng X, Bhan U, Lukacs NW, Kunkel SL, and Standiford TJ (2010) Critical role of IL-1 receptor- Associated kinase-M in regulating chemokine-dependent deleterious inflammation in murine influenza pneumonia. J Immunol 184:1410-1418.
32. Sethi S, Evans N, Grant BJ, and Murphy TF (2002) New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 347:465-471.
33. Spagnolo P, Fabbri LM, and Bush A (2013) Long- Term macrolide treatment for chronic respiratory disease. Eur Respir J 42:239-251.
34. Sun K and Metzger DW (2008) Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 14:558-564.
35. Tate MD, Deng YM, Jones JE, Anderson GP, Brooks AG, and Reading PC (2009) Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J Immunol 183:7441-7450.
36. Trinchieri G (2010) Type I interferon: friend or foe? J Exp Med 207:2053-2063.
37. van der Sluijs KF, van der Poll T, Lutter R, Juffermans NP, and Schultz MJ (2010) Bench- To-bedside review: bacterial pneumonia with influenza-pathogenesis and clinical implications. Crit Care 14:219.
38. Yamaryo T, Oishi K, Yoshimine H, Tsuchihashi Y, Matsushima K, and Nagatake T (2003) Fourteen-member macrolides promote the phosphatidylserine receptordependent phagocytosis of apoptotic neutrophils by alveolar macrophages. Antimicrob Agents Chemother 47:48-53.
39. Yamaya M, Azuma A, Takizawa H, Kadota J, Tamaoki J, and Kudoh S (2012) Macrolide effects on the prevention of COPD exacerbations. Eur Respir J 40: 485-494.
40. Yamaya M, Shinya K, Hatachi Y, Kubo H, Asada M, Yasuda H, Nishimura H, and Nagatomi R (2010) Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J Pharmacol Exp Ther 333:81-90.
41. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, and Zarogoulidis K (2012) Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 68: 479-503.